Metrics as of 10/15/2026, 08:31 AM (Berlin time), refresh in progress.
Glaukos Stock
Glaukos Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Thomas William Burns
- Employees
- 1,094
- Market cap
- $9.9 B
- IPO
- 25/06/2015
Glaukos Corporation operates as a specialized company in the healthcare/medical device sector, primarily focusing on ophthalmic medical technology and pharmaceuticals. Its focus lies on innovative therapies for glaucoma, corneal diseases, and retinal issues. The portfolio includes various stents such as the iStent,…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Glaukos stock: price history
1D
+1.4%
1W
-2.5%
1M
-1.9%
6M
+38.8%
YTD
+48.7%
1Y
+96.8%
2Y
+29.1%
5Y
+274.6%
10Y
+371.3%
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~43% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Glaukos stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Glaukos Corporation is a specialized medical device company focused on developing and commercializing therapies for ophthalmic diseases such as glaucoma, corneal and retinal disorders. The core product portfolio comprises various micro-bypass stents as well as innovative implantable drug delivery systems utilizing a proprietary platform. Sales are conducted through a dedicated sales organization and an international network of distributors, with primary focus on the glaucoma treatment market.
- Revenue model
- Transactional
- Recurring revenue
- Low
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Glaukos
Analyst assessment of Glaukos
PRICE TARGET LOW
US$150.00
CONSENSUS
US$192.90
MEDIAN
US$195.00
PRICE TARGET HIGH
US$215.00
0
STRONG BUY
18
BUY
6
HOLD
1
SELL
0
STRONG SELL
25
TOTAL · Buy
As of: 12/10/2026
Glaukos stock metrics
P/E
-51.66
P/B
14.37
EV/EBITDA
-70.15
RETURN ON EQUITY
-2.7%
NET MARGIN
-9.9%
DEBT/EQUITY
0.15
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.0%
FLOAT SHARES
56,642,357
AVG. DAILY VOLUME (30D)
940,955
Insider transactions (SEC)
Navratil Tomas
Navratil Tomas
Navratil Tomas
Navratil Tomas
Navratil Tomas
Attention
Price since yesterday: +1.4%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Glaukos stock
What does Glaukos do?
Glaukos Corporation is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Thomas William Burns, the company employs around 1,094 people.
The IPO was on 25/06/2015; the stock trades on NYSE under the ticker GKOS.
What do analysts say about Glaukos stock?
25 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$192.90, ranging from US$150.00 to US$215.00, with a median of US$195.00.
This is an external assessment, not a statement by Market Jury.
When does Glaukos report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly 43% stronger than usual.
Does Glaukos pay a dividend?
No, Glaukos currently does not pay a dividend.
Which stocks are comparable to Glaukos?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Glaukos stock analyzed?
Clicking "Analyze stock" lets five strategies assess Glaukos against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.